Long-term analysis supports previous head-to-head data.

Those on systemic therapy had no increased risk.

The varied response of patients to ustekinumab is not well understood.

Little is known about the real-world effectiveness and safety of apremilast.

A promising therapy for maintenance of clinical efficacy.

Little is known about the long-term drug survival of infliximab.

The debut of several new treatment options necessitates comparative safety studies.

Safety in this population has not been well characterized

Metformin improved some metabolic parameters and clinical outcomes.

Meta-analysis clarifies cancer risk for patients with psoriatic arthritis and those treated with biologics.

Achieving the lowest effect dose may help reduce the risk and financial burden of biologic therapy.

This patient population needs effective, well-tolerated systemic therapies.

Many available treatment options for psoriasis do not adequately address pruritus.

Few studies have evaluated the link between HZ and CISD, which share several risk factors.